Quizartinib for the treatment of acute myeloid leukemia.
Alejandro Garcia-HortonKaren Wl YeePublished in: Expert opinion on pharmacotherapy (2020)
. Quizartinib yielded an improvement in OS and complete remission (CR) rates in a phase 3 trial for relapsed/refractory FLT3-mutated AML. The toxicities are manageable; however, it is associated with significant QTc prolongation and myelosuppression. The FDA and EMA did not grant drug approval to quizartinib in the relapsed/refractory setting due to the lack of a significant benefit - to-risk ratio, safety concerns and concerns with credibility and generalizability of the trial data. Results from the frontline phase 3 study evaluating quizartinib with intensive chemotherapy are eagerly awaited. Ongoing studies are investigating its toxicity and efficacy with other therapeutic agents and will help to clarify its role in the treatment of FLT3-ITD-mutated AML.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- clinical trial
- randomized controlled trial
- open label
- acute lymphoblastic leukemia
- electronic health record
- combination therapy
- study protocol
- replacement therapy
- smoking cessation
- tyrosine kinase
- hodgkin lymphoma
- ulcerative colitis
- double blind
- drug administration